according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

SECTION 1. IDENTIFICATION

Product name : Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Serious eye damage : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity

- single exposure (Oral)

Category 2 (Central nervous system)

Specific target organ toxicity

- repeated exposure

Category 2 (Brain, Liver)

Specific target organ toxicity

- repeated exposure (Oral)

Category 2 (Blood, Testis)

GHS label elements

Hazard pictograms





Signal Word : Danger

Hazard Statements : H318 Causes serious eye damage.

H361d Suspected of damaging the unborn child.

H371 May cause damage to organs (Central nervous system) if

swallowed.

H373 May cause damage to organs (Brain, Liver) through pro-

longed or repeated exposure.

H373 May cause damage to organs (Blood, Testis) through

prolonged or repeated exposure if swallowed.

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Precautionary Statements

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapors.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER.

P308 + P311 IF exposed or concerned: Call a doctor.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | Common Name/Synonym | CAS-No. | Concentration (% w/w) |
|-------------------------------|---|------------|-----------------------|
| Oxyclozanide | 3,3',5,5',6- Pentachloro-2'- hydroxysalicy- lanilide | 2277-92-1 | 13 |
| Silicic acid, aluminum salt | No data availa- ble | 1335-30-4 | 6.51 |
| Levamisole hydrochlo- ride | No data availa- ble | 16595-80-5 | 6.5 |
| Citric acid | 2- hydroxypro- pane-1,2,3- tricarboxylic acid | 77-92-9 | 1.77 |

SECTION 4. FIRST AID MEASURES

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 10857718-00005 2.2 09/30/2023 Date of first issue: 09/29/2022

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of contact, immediately flush eyes with plenty of water In case of eye contact

for at least 15 minutes.

If easy to do, remove contact lens, if worn. Get medical attention immediately.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

Causes serious eye damage. Suspected of damaging the unborn child.

May cause damage to organs if swallowed.

May cause damage to organs through prolonged or repeated

exposure.

Protection of first-aiders First Aid responders should pay attention to self-protection.

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Hazardous combustion prod-

Exposure to combustion products may be a hazard to health.

Carbon oxides

Chlorine compounds Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emergency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Advice on safe handling :

Use only with adequate ventilation. Do not breathe mist or vapors.

Do not swallow. Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis | |
|-----------------------------|---------------------------|-------------------------------------|--|-----------|--|
| Oxyclozanide | 2277-92-1 | TWA | 0.4 mg/m3 (OEB 2) | Internal | |
| Silicic acid, aluminum salt | 1335-30-4 | TWA | 2 mg/m³ (Aluminum) | CA AB OEL | |
| | | TWAEV (respirable dust) | 5 mg/m³ | CA QC OEL | |
| Levamisole hydrochloride | 16595-80-5 | TWA | 20 μg/m3 (OEB 3) | Internal | |
| | Further information: Skin | | | | |
| | | Wipe limit | 200 μg/100 cm ² | Internal | |

Engineering measures: Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Color : yellow

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 2.2 10857718-00005 Date of first issue: 09/29/2022

Not applicable

No data available

Solubility(ies)

No data available Water solubility

Partition coefficient: n-

Autoignition temperature

octanol/water

Decomposition temperature No data available

Viscosity

Viscosity, kinematic No data available

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions Conditions to avoid

None known. Incompatible materials Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Oxyclozanide:

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg

Target Organs: Central nervous system

Acute toxicity (other routes of :

administration)

LDLo (sheep): 10 mg/kg

Application Route: Intravenous

Silicic acid, aluminum salt:

Acute oral toxicity : LD50 (Rat, female): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Remarks: Based on data from similar materials

Levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg

LD50 (Mouse): 223 mg/kg

LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

Silicic acid, aluminum salt:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Levamisole hydrochloride:

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Remarks : No data available

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

Silicic acid, aluminum salt:

Species : Chicken eye

Method : Chorioallantoic membrane vascularization assay

Result : Irreversible effects on the eye

Levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Oxyclozanide:

Routes of exposure : Dermal

Remarks : Not classified due to lack of data.

Silicic acid, aluminum salt:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact Species : Mouse

Method : OECD Test Guideline 429

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Result : negative

Levamisole hydrochloride:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Oxyclozanide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Test Type: Mouse Lymphoma

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Silicic acid, aluminum salt:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Oxyclozanide:

Remarks : Not classified due to lack of data.

Silicic acid, aluminum salt:

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
Result : negative

Remarks : Based on data from similar materials

Levamisole hydrochloride:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

NOAEL : 80 mg/kg body weight

Remarks : No significant adverse effects were reported

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 40 mg/kg body weight

Remarks : No significant adverse effects were reported

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat, male and female

Application Route: Oral

General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal

and postnatal development. Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal

and postnatal development. Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: LOAEL: 75 - 100 mg/kg body

weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on

fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 100 mg/kg body weight

Result: No fetotoxicity., No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Developmental Toxicity: NOAEL: 32 mg/kg body weight

Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

Silicic acid, aluminum salt:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 20 mg/kg body weight

Result: Fetotoxicity.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Oxyclozanide:

Routes of exposure : Oral

Target Organs : Central nervous system
Assessment : May cause damage to organs.

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Citric acid:

Assessment : May cause respiratory irritation.

STOT-repeated exposure

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.

May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swal-

lowed.

Components:

Oxyclozanide:

Target Organs : Brain, Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Levamisole hydrochloride:

Target Organs : Blood, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Oxyclozanide:

Species : Rat
NOAEL : 9 mg/kg
LOAEL : 44.5 mg/kg
Application Route : Oral
Exposure time : 3 Months

Target Organs : Brain, Liver, spleen, Adrenal gland

Symptoms : Liver effects

Species : Dog
NOAEL : 5 mg/kg
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Brain, Liver

Symptoms : blood effects, alteration in liver enzymes

Silicic acid, aluminum salt:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 104 Weeks

Remarks : Based on data from similar materials

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Levamisole hydrochloride:

Species : Rat
NOAEL : 2.5 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 18 Months Target Organs : Blood

Species : Dog LOAEL : 40 mg/kg Application Route : Oral Exposure time : 3 Months

Citric acid:

Species : Rat

NOAEL : 4,000 mg/kg LOAEL : 8,000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Components:

Oxyclozanide:

Not applicable

Experience with human exposure

Components:

Oxyclozanide:

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central

nervous system depression

Levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypo-

tension

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Oxyclozanide:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.69 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Silicic acid, aluminum salt:

Ecotoxicology Assessment

Chronic aquatic toxicity : No toxicity at the limit of solubility.

Levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 64 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,535 mg/l

Exposure time: 24 h

Persistence and degradability

Components:

Oxyclozanide:

Stability in water : Hydrolysis: 50 %(156 d)

Method: OECD Test Guideline 111

Citric acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Bioaccumulative potential

Components:

Oxyclozanide:

Partition coefficient: n- : log Pow: 3.99

octanol/water pH: 7

Method: OECD Test Guideline 107

Citric acid:

Partition coefficient: n-

octanol/water

log Pow: -1.72

Mobility in soil

Components:

Oxyclozanide:

Distribution among environ-

mental compartments

log Koc: 4.83

Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxyclozanide)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Oxyclozanide)

Class : 9

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen: 964

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Oxyclozanide)

Class : 9
Packing group : III
Labels : 9

EmS Code : F-A, S-F Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Oxyclozanide)

Class : 9
Packing group : III
Labels : 9
ERG Code : 171

Marine pollutant : yes(Oxyclozanide)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

CA AB OEL / TWA : 8-hour Occupational exposure limit CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk: IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

according to the Hazardous Products Regulations



Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 2.2 09/30/2023 10857718-00005 Date of first issue: 09/29/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8